Skip to main content

Table 3 Participants’ health status at week 26 (FAS, ANCOVA, LOCF)

From: Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Health status Placebo (n = 63) Rasagiline 1 mg (n = 64) P value
PDQ-39 Dimension
 Summary index 1.97 ± 1.15 0.77 ± 1.12 0.425
Activities of daily living
 Change from baseline 2.49 ± 1.82 1.86 ± 1.79 0.789
Bodily discomfort    
 Change from baseline 1.28 ± 2.05 2.14 ± 2.01 0.749
Cognition
 Change from baseline 1.60 ± 1.91 −1.97 ± 1.87 0.156
Communication
 Change from baseline 2.10 ± 1.45 1.41 ± 1.42 0.716
Emotional well-being
 Change from baseline 1.43 ± 1.82 −1.62 ± 1.78 0.201
Mobility
 Change from baseline 3.13 ± 1.83 2.60 ± 1.79 0.823
Social support
 Change from baseline 2.91 ± 1.16 2.56 ± 1.14 0.819
Stigma
 Change from baseline 0.59 ± 2.16 −1.32 ± 2.12 0.502
EQ-5D score
EQ-5D Utility index score
 Change from baseline −0.04 ± 0.02 −0.01 ± 0.02 0.261
EQ-5D VAS score
 Change from baseline −4.31 ± 1.65 2.49 ± 1.61 0.002
  1. Data are mean ± standard error of the mean. EQ-5D, EuroQol-Five Dimension; PDQ-39, Parkinson’s Disease Questionnaire-39; VAS, visual analog scale